NJ-RUNPOD
8.5.2024 15:08:27 CEST | Business Wire | Press release
RunPod, the launchpad that empowers developers to deploy custom full-stack AI applications, today announced it raised $20M in Seed funding, co-led by Intel Capital and Dell Technologies Capital with participation from Julien Chaummond, Nat Friedman, and Adam Lewis. In conjunction with the financing, Mark Rostick, Vice President and Senior Managing Director at Intel Capital, will join RunPod’s board of directors.
RunPod is a globally distributed GPU cloud computing service for training, deploying, and scaling AI models. Using RunPod’s two core products, GPU Cloud and Serverless, developers can spin up an on-demand GPU instance in a few clicks and create autoscaling API endpoints for scaling inference on AI models in production.
“The ability to create and deploy AI applications at scale will be paramount to their adoption and utilization,” said Amjad Masad, RunPod investor. “The RunPod team has clearly prioritized the developer experience to create an elegant solution that enables individuals to rapidly develop custom AI apps or integrations while also paving the way for organizations to truly deliver on the promise of AI.”
RunPod makes it simple for developers to seamlessly run any GPU workload, allowing them to focus less on Machine Learning operations and more on building their applications. These capabilities have proven advantageous to developers and resulted in RunPod’s swift expansion with 10-fold revenue growth year over year.
“RunPod started as a playground for developers and innovators, a place where they went to do their research, develop and finetune their projects; now, it boasts a community of over 100K developers,” said Zhen Lu, co-founder and CEO of RunPod. “We’ve grown so quickly because RunPod strikes the perfect balance between providing developers with the freedom to launch whatever they want, while still having the necessary infrastructure and tools in place to assist in the customization, development, and deployment of differentiated products.”
The emergence of AI-specific workloads has given rise to increased computational demands. Once the go-to solution, out-of-the-box cloud infrastructure platforms are no longer cost-effective or fast enough to create custom-differentiated products. With RunPod, developers can reliably and simply develop, train, scale, and launch custom full-stack AI applications or integrations in the cloud on a global scale.
“RunPod is rapidly growing both its customer base and revenue by offering a broad, fast, and easy-to-use platform that meets the needs of developers and their model-based applications," said Mark Rostick, Vice President and Senior Managing Partner at Intel Capital. “I’ve watched RunPod’s momentum scale from a small startup offering individual developers an ecosystem to kickstart their research and development to a serverless offering that allows enterprise customers to scale their customized high-grade products and solutions.”
Rapid growth and developer adoption created the need to grow the team almost 10x in the past year, establishing itself as a leader pioneering GPU AI-powered transformation. The platform has recently launched the ability to deploy CPU compute instances, a huge milestone in creating a holistic cloud solution. This Seed funding will enable RunPod to enhance the day-to-day life of developers, form new partnerships and integrations for seamless user experiences, and offer new and existing customers the perfect foundation for developing custom AI models.
“As the enterprise deploys more AI applications into production, the key to their success is access to fast, reliable, and scalable infrastructure. This is what Zhen, Pardeep, and the team have built with the RunPod platform,” said Radhika Malik, Partner at Dell Technologies Capital. “They are committed to keeping the dev experience central to everything they do. That’s resulted in overwhelmingly positive sentiment from the community and impressive, sustained user growth.”
About RunPod:
RunPod is a globally distributed GPU cloud platform that empowers developers to deploy custom full-stack AI applications – simply, globally, and at scale. With RunPod’s key offerings, GPU Instances and Serverless GPUs, developers can develop, train and scale AI applications in one cloud within seconds. RunPod is committed to making cloud computing accessible and affordable without compromising features, usability, or experience. It strives to empower individuals and enterprises with cutting-edge technology, enabling them to unlock the potential of AI and cloud computing. To learn more about RunPod, visit https://www.runpod.io/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508053225/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Delivers Fourth Quantum Computer in Finland, Operational at Aalto University11.3.2026 11:32:00 CET | Press release
This is the fourth quantum computer deployed by IQM to customers in Finland to boost research and education in a growing ecosystem. The system named Aalto Q20 quantum computer is online at Aalto University and will enable students and scientists a unique first-hand access to a world-class quantum computer. The university will use the quantum computer to perform scientific experiments on advanced level and to support national and European quantum research activities. IQM Quantum Computers, the global leader in deployed on-premises, full-stack superconducting quantum computers, today announced the launch of Aalto Q20 quantum computer in Finland, reinforcing its commercial leadership in the quantum industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311215316/en/ Ribbon cutting of the Aalto Q20 quantum computer delivered by IQM. The 20-qubit system, which is operational at Aalto University, is the fourth quantum compute
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site11.3.2026 11:00:00 CET | Press release
Highlights Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissionsBespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resiliencePartnership aligns with the science-based climate commitments of both companies Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program. This press release features multi
NTT DATA Unveils NVIDIA-Powered Enterprise AI Factories to Support Secure AI Adoption and Help Clients Drive Measurable ROI11.3.2026 11:00:00 CET | Press release
NTT DATA drives success in healthcare, manufacturing and other sectors with NVIDIA-powered technologies NTT DATA AI solutions now integrate NVIDIA AI Enterprise software, including NVIDIA NeMo and NIM Microservices to create a full-stack, production-ready, GPU-accelerated agentic AI platform NTT DATA, a global leader in AI, digital business and technology services, announced an initiative to deliver NVIDIA-powered enterprise AI factories that drive innovation and operational excellence for organizations worldwide. NTT DATA’s new enterprise AI factories provide full-stack, domain-specific solutions that integrate data, infrastructure, workflows and governance to give organizations a repeatable and production-ready operating model for enterprise AI. NTT DATA enterprise AI factories, powered by NVIDIA, are adaptive, intelligent and automated ecosystems designed to help clients accelerate return on investment by scaling enterprise AI efficiently and managing the full AI lifecycle end to en
Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health11.3.2026 10:00:00 CET | Press release
£65m investment in new oral health manufacturing plant in Shanghai to support growth in the world’s largest gum health market Haleon aiming to extend gum health brand parodontax to 30 Chinese cities by end of 2027 - including its fastest growing cities – reaching aspirational shoppers in-store and online Custom designed taste, foamier sensation and premium packaging to appeal to local consumers Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 09:00:00 CET | Press release
Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
